Irican (Irinotecan Hydrochloride Trihydrate)

Irican belongs to the topoisomerase I inhibitor class and is used in cancers that rely on rapid DNA replication.

• Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based regimens.
• Adjuvant treatment of colon cancer: reduces risk of disease recurrence after surgical resection.
• Small cell lung cancer: provides therapeutic benefit as part of combination chemotherapy protocols.

• Irinotecan is a pro‑drug that is converted intracellularly to SN‑38, a potent inhibitor of topoisomerase I. By stabilising the enzyme‑DNA cleavable complex, it prevents religation of single‑strand DNA breaks, leading to accumulation of DNA damage and ultimately tumour cell apoptosis.

Irinotecan is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Diarrhea: often delayed and may be severe.
• Nausea and vomiting: typically manageable with anti‑emetics.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Alopecia: temporary hair loss.
• Fatigue: generalized tiredness during treatment cycles.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophil count requiring urgent care.
• Severe colitis or bowel perforation: life‑threatening gastrointestinal complications.
• Anaphylactic reactions: rare but may occur during infusion.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.

Before initiating Irican therapy, clinicians should assess patient‑specific factors and monitor for toxicity.

• Monitor blood counts: perform regular complete blood count to detect neutropenia.
• Assess liver function: adjust dosing in hepatic impairment.
• Evaluate bowel status: avoid use in patients with recent abdominal surgery or obstruction.
• Use anti‑emetics prophylactically: to reduce nausea and vomiting.
• Adjust dose for UGT1A1 polymorphisms: consider genetic testing where available.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce irinotecan exposure.
• UGT1A1 inhibitors (e.g., atazanavir): can increase SN‑38 levels and risk of severe neutropenia.
• Concurrent myelosuppressive agents: heighten risk of bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly increase exposure.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters due to potential bleeding risk.
• NSAIDs or aspirin: may exacerbate gastrointestinal toxicity.